Phase 2 Kidney Cancer Trial, Recruiting (NCT06680089)

Phase 2 Kidney Cancer Trial, Recruiting NCT06680089 Sponsor: RenJi Hospital Condition: Kidney Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06680089 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Kidney Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People between 18 and 80 years old, of any sex
People who have been diagnosed with kidney cancer (particularly certain types called clear cell renal cell carcinoma or papillary renal cell carcinoma) confirmed by a tissue sample, or who have a suspected kidney cancer identified through medical imaging
People who are able to give their written agreement to participate and follow the requirements of the trial

Who may not be able to join:

People who are pregnant
People who have seriously reduced liver or kidney function
People who have had major surgery within the last month
People who have had an allergic reaction to a type of medication called antibody or single-domain antibody radiopharmaceuticals (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Wei Zhai, Ph.D. & M.D., Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Phone: 15000083153

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06680089

Sponsor: RenJi Hospital

Phase: Phase 2

Status: Recruiting

Condition: Kidney Cancer

Trial contact: 15000083153

More information: https://clinicaltrials.gov/study/NCT06680089

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People between 18 and 80 years old, of any sex
People who have been diagnosed with kidney cancer (particularly certain types called clear cell renal cell carcinoma or papillary renal cell carcinoma) confirmed by a tissue sample, or who have a suspected kidney cancer identified through medical imaging
People who are able to give their written agreement to participate and follow the requirements of the trial

Who may not be able to join:

People who are pregnant
People who have seriously reduced liver or kidney function
People who have had major surgery within the last month
People who have had an allergic reaction to a type of medication called antibody or single-domain antibody radiopharmaceuticals (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

RenJi Hospital

Registry

ClinicalTrials.gov

Start date

27 November 2024

Est. completion

1 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Biodistribution of [18F]RCCB6; Standardized uptake value (SUV); The correlation between CD70 expression and [18F]RCCB6 uptake value; Diagnostic value of [18F]RCCB6 PET in patients with ccRCC; To explore the diagnostic performance of [18F]RCCB6 PET with that of conventional imaging and [18F]FDG PET

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov